Alisertib
Alisertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against aurora kinase A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| T-cell lymphoma peripheral | D016411 | — | — | 2 | 2 | 1 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 20 | 4 | — | — | — | 23 |
| Lymphoma | D008223 | — | C85.9 | 9 | 2 | — | — | — | 11 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 5 | — | — | — | 8 |
| Recurrence | D012008 | — | — | 4 | 4 | — | — | — | 8 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 5 | 3 | — | — | — | 7 |
| B-cell lymphoma | D016393 | — | — | 5 | 1 | — | — | — | 6 |
| Follicular lymphoma | D008224 | — | C82 | 5 | 2 | — | — | — | 6 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 4 | 3 | — | — | — | 6 |
| Burkitt lymphoma | D002051 | — | C83.7 | 4 | 3 | — | — | — | 6 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 2 | — | — | — | 5 |
Show 58 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | 2 | — | — | — | — | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 2 | — | — | — | — | 2 |
| Digestive system neoplasms | D004067 | — | — | 2 | — | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | — | — | — | — | 2 |
| Laryngeal diseases | D007818 | — | J38.7 | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Mucinous adenocarcinoma | D002288 | — | — | 1 | — | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | 1 | — | — | — | — | 1 |
Show 31 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary myelofibrosis | D055728 | — | D47.4 | — | — | — | — | 1 | 1 |
| Megakaryoblastic leukemia acute | D007947 | — | C94.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alisertib |
| INN | alisertib |
| Description | 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid is a benzazepine. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 1028486-01-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL483158 |
| ChEBI ID | — |
| PubChem CID | 24771867 |
| DrugBank | DB05220 |
| UNII ID | T66ES73M18 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
EPHA2
EPHA2
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,064 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
119 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use